IFP Advisors’s Pyxis Oncology PYXS Stock Holding History

IFP Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17	Closed	-$17	–	5001
2025 Q1	$17	Hold	17	–	–	﹤0.01%	4189
2024 Q4	$27	Buy	+17	New	+$49	﹤0.01%	4406

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's PYXS Position: Q2 2025 in Review

IFP Advisors sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 17 shares — an estimated $17 sold.

IFP Advisors first reported a position in PYXS in Q4 2024 and held it in 2 quarters. The position peaked at $27 in Q4 2024. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

IFP Advisors reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 17 Pyxis Oncology shares in Q2 2025, an estimated $17.
IFP Advisors first reported a position in Pyxis Oncology in Q4 2024 and held it in 2 quarters.
IFP Advisors's Pyxis Oncology position peaked at $27 in Q4 2024.
74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.